Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

@article{Pfirrmann2016PrognosisOL,
  title={Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia},
  author={Markus Pfirrmann and Michele Baccarani and Susanne Saussele and Joelle Guilhot and Francisco Cervantes and Gert Jan Ossenkoppele and Verena Sophia Hoffmann and Fausto Castagnetti and J. Hasford and Rȕdiger Hehlmann and Bengt Simonsson},
  journal={Leukemia},
  year={2016},
  volume={30},
  pages={48-56}
}
In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to CML. This work tackled the reassessment of prognosis under particular consideration of the probabilities of dying of CML. Analyses were based on 2290 patients with chronic phase CML treated with imatinib in six clinical trials. ‘Death due to CML’ was defined by death after disease progression. At 8 years, OS was… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Differences among young adults, adults and elderly chronic myeloid leukemia patients.

Annals of oncology : official journal of the European Society for Medical Oncology • 2015

Frontline treatment with imatinib mesylate in chronic myeloid leukemia patients in early chronic phase: a very long-term analysis by the GIMEMA CML Working Party

F Castagnetti, G Gugliotta, +3 authors A Capucci
Blood • 2013

Similar Papers

Loading similar papers…